Table 1.
Characteristics of Those With Acromegaly Before and After Surgery or Pegvisomant Therapy
| Characteristic | Acromegaly Surgery Group | Acromegaly Pegvisomant Group | ||||
|---|---|---|---|---|---|---|
| Before Surgery | After Surgerya | P Value | Before Pegvisomant | After Pegvisomanta | P Value | |
| Sex, n | ||||||
| Male | 8 | 8 | 6 | 6 | ||
| Female | 5 | 5 | 4 | 4 | ||
| Age, y | 44 (22–62) | 45 (24-63) | 0.001 | 42.5 (21–62) | 44 (21–64) | 0.004 |
| Previous therapy | S (n = 10), C (n = 3), SA (n = 10), RT (n = 4) | |||||
| Fasting GH, µg/L | 11 (5.9–87.7) | 0.43 (0.05–2) | 0.0002 | 5.6 (2.3–75.8) | 11.3 (6.6–133) | 0.03 |
| IGF-I, µg/L | 603 (482–994) | 200 (110–533) | 0.0002 | 555 (406–785) | 263 (156–422) | 0.002 |
| BMI, kg/m2 | 29.5 (22.4–44) | 31 (22.4–44) | 0.22 | 30.3 (27.5–35.6) | 30.9 (25.4–66.2) | 0.85 |
Data presented as median (range).
Abbreviations: C, cabergoline; RT, radiotherapy; S, transsphenoidal surgery; SA, long-acting somatostatin analog.
a
Data from the last visit included in the present study.